# MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

> **NCT04032626** · PHASE2 · COMPLETED · sponsor: **St. Joseph's Hospital and Medical Center, Phoenix** · enrollment: 15 (actual)

## Conditions studied

- Cognitive Impairment, Mild
- Cognitive Dysfunction
- Amyloid Plaque
- Neurodegeneration
- Inflammation, Brain

## Interventions

- **DRUG:** Lenalidomide 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04032626
- **Lead sponsor:** St. Joseph's Hospital and Medical Center, Phoenix
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04032626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04032626, "MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04032626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*